NCT05151718 Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents
| NCT ID | NCT05151718 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Claudius Regaud |
| Condition | Ependymoma of Brain |
| Study Type | OBSERVATIONAL |
| Enrollment | 370 participants |
| Start Date | 2021-09-30 |
| Primary Completion | 2026-06-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 370 participants in total. It began in 2021-09-30 with a primary completion date of 2026-06-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Treatment of childhood ependymoma, the second most frequent pediatric brain tumor, is based on surgery and radiation therapy. However, 50% relapse, mainly locally. Progress in imaging, molecular biology and radiotherapy ballistics has led us to propose the EPENDYMOMICS project, a multi-omics approach using artificial intelligence to detect the predictive characteristics of relapse, and to define innovative radiotherapy targets using multimodal imaging. We previously reported that the relapse sites are mainly located in the high-dose radiotherapy zone and that there appear to be prognostic factors for relapse based on anatomical and functional MRI abnormalities by diffusion and perfusion. In addition, recent studies in molecular biology have identified significant prognostic factors. The challenge now is to use and correlate all these findings in larger cohorts to tackle the radio-resistance of this disease. Our objective is to collate in a single database called NETSPARE (Network to Structure and Share Pediatric data to Accelerate Research on Ependymoma) the clinical, histological, biological, imaging and radiotherapy data from two consecutive studies that included 370 children and adolescents with ependymoma since 2000 in France. The EPENDYMOMICS project will comprise a clinical research team, three imaging research teams, two histopathology teams, and a biostatistics team working on NETSPARE. Our goal is to obtain a radiogenomic signature of our data, which will be validated with the English external cohort of 200 patients that is currently being analyzed. The perspective is to optimize the indications and volumes of irradiation that could in the future be used in a European translational research trial to tackle radioresistance.
Eligibility Criteria
Inclusion Criteria: * children with intracranial ependymoma * treated * included in PEPPI study, pediaRT or in SIOP II Ependymoma french program Exclusion Criteria: * NA
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05151718 clinical trial?
This trial is open to participants of all sexes, up to 25 Years, studying Ependymoma of Brain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05151718 currently recruiting?
Yes, NCT05151718 is actively recruiting participants. Contact the research team at laprie.anne@iuct-oncopole.fr for enrollment information.
Where is the NCT05151718 trial being conducted?
This trial is being conducted at Toulouse, France.
Who is sponsoring the NCT05151718 clinical trial?
NCT05151718 is sponsored by Institut Claudius Regaud. The trial plans to enroll 370 participants.